Biopharmaceutical News and Research

RSS
Lipocine announces favorable Phase I study results for LPCN 1111

Lipocine announces favorable Phase I study results for LPCN 1111

8 Apr 2013
GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics announces closing of €32 million Series A financing

8 Apr 2013
Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

8 Apr 2013
Dual challenges of Medical Education groups

Dual challenges of Medical Education groups

6 Apr 2013
Agios, Foundation Medicine announce diagnostic partnership for cancer metabolism programs

Agios, Foundation Medicine announce diagnostic partnership for cancer metabolism programs

4 Apr 2013
BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

3 Apr 2013
Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics raises $33M in Series E financing

2 Apr 2013
NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

2 Apr 2013
N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

2 Apr 2013
CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

28 Mar 2013
Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

28 Mar 2013
FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

27 Mar 2013
Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

27 Mar 2013
Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

26 Mar 2013
arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X advances ARGX-112 into formal preclinical development

25 Mar 2013
Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

24 Mar 2013
Chimerix receives FDA Fast Track designation for CMX001 to prevent CMV infection

Chimerix receives FDA Fast Track designation for CMX001 to prevent CMV infection

12 Mar 2013
Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

12 Mar 2013
Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

12 Mar 2013
FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

11 Mar 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback